Showing 791-800 of 3103 results for "".
Lidocaine Shortage Update
https://practicaldermatology.com/conferences/scale-2023/lidocaine-shortage-update/20196/The current lidocaine and lidocaine with epinephrine shortage is affecting practices across the country. Joel L. Cohen, MD, and George Hruza, MD, weigh in on the shortage and potential solutions and how to minimize toxicity risks when mixing and matching different anesthetics.How Incyte Is Following the Science to Develop Innovative Solutions for Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/atopic-dermatitis/how-incyte-is-following-the-science-to-develop-innovative-solutions-for-immune-mediated-skin-conditions/20158/Jim Lee, head of the Inflammation and Autoimmunity clinical development group at Incyte, discusses the role of the immune system in atopic dermatitis (AD) and vitiligo and shares how Incyte is following the science to develop innovative options impacting the lives of people with these conditions.Leadership Pearls from a High-Performing Practice
https://practicaldermatology.com/topics/practice-management/leadership-pearls-from-a-high-performing-practice/23777/A successful practice shares tips for growth.Scientifically Speaking: Investing in Innovation with Humberto Antunes
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-investing-in-innovation-with-humberto-antunes/20128/With decades of experience in dermatology and aesthetics, Humberto Antunes has helped to identify some key innovations in the field. Now part of Gore Range Capital, he continues to look for the next game-changer. He discusses his experience and shares insights on the specialties with host Joel L. CoTolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pConsidering Liver Health in Psoriasis: New Assessment Options
https://practicaldermatology.com/topics/psoriasis/considering-liver-health-in-psoriasis-new-assessment-options/23429/A rapid, non-invasive liver exam addresses growing need for early identification and monitoring of liver disease among patients with psoriasis.DermWireTV: Doximity Physician Compensation Report, EADV Updates, PsO in the Know
https://practicaldermatology.com/topics/psoriasis/dermwiretv-doximity-physician-compensation-report-eadv-updates-pso-in-the-know/19870/Doximity’s fourth annual Physician Compensation Report shows a widening of the gender pay gap. From biologics and investigational molecules for psoriasis to socks to prevent foot odors, the European Academy of Dermatology and Venereology annual meeting highlights emerging therapies for dermatology pDermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin
https://practicaldermatology.com/topics/psoriasis/dermwiretv-clinical-support-tech-data-dupixent-stelara-updates-rihanna-launches-fenty-skin/19835/A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potentiaThe 401K Today: What Every Dermatology Practice Should Know
https://practicaldermatology.com/topics/practice-management/the-401k-today-what-every-dermatology-practice-should-know/21414/How to ensure you're in compliance with the DOL's revised ERISA rules governing 401K plans.Topical Corticosteroids and Topical Calcineurin Inhibitors in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/topical-corticosteroids-and-topical-calcineurin-inhibitors-atopic-dermatitis/29118/Analysis of a 2024 study by Gether et al., in which the authors compared the effectiveness of topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) in adults with atopic dermatitis (AD).